Water Vapor Ablation for Prostate Cancer: Long-Term Registry
NCT: NCT07455058 · RECRUITING
Brief Summary
The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of patients who have received or will receive the therapy one or multiple times as part of routine clinical care and encompasses those who completed a company-sponsored Vanquish therapy study (as applicable).
Frequently Asked Questions
What is Water Vapor Ablation for Prostate Cancer: Long-Term Registry?
Water Vapor Ablation for Prostate Cancer: Long-Term Registry is a clinical trial registered under NCT07455058. Current status: RECRUITING.
What is the status of NCT07455058?
The current status of NCT07455058 (Water Vapor Ablation for Prostate Cancer: Long-Term Registry) is: RECRUITING.
When did Water Vapor Ablation for Prostate Cancer: Long-Term Registry start?
Water Vapor Ablation for Prostate Cancer: Long-Term Registry started on 2026-06-05.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.